IL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice

Hepatology

Volumn 45, Issue 2, 2007, Pages 475-485

  Erhardt, Annette ^a   Biburger, Markus ^a   Papadopoulos, Thomas ^a   Tiegs, Gisa ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONCANAVALIN A; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL CULTURE; CELL FUNCTION; CELLULAR IMMUNITY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; IN VITRO STUDY; KUPFFER CELL; LIVER INJURY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL;

ANIMALS; ANTIGENS, CD4; CELLS, CULTURED; CONCANAVALIN A; DRUG TOLERANCE; HEPATITIS, TOXIC; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KUPFFER CELLS; LIVER; MALE; MICE; MICE, KNOCKOUT; MITOGENS; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY;

EID: 33847727077     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21498     Document Type: Article

References (50)

1. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003;3:51-62.
2. Bishop GA, McCaughan GW. Immune activation is required for the induction of liver allograft tolerance: implications for immunosuppressive therapy. Liver Transpl 2001;7:161-172.
3. Bowen DG, McCaughan GW, Bertolino P. Intrahepatic immunity: a tale of two sites? Trends Immunol 2005;26:512-517.
4. Klugewitz K, Adams DH, Emoto M, Eulenburg K, Hamann A. The composition of intrahepatic lymphocytes: shaped by selective recruitment? Trends Immunol 2004;25:590-594.
5. Tiegs G, Hentschel J, Wendel A. A T-cell dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992;90:196-203.
6. Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F, et al. Augmentation of Vα 14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000;191:105-114.
7. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 2000;97:5498-5503.
8. Schümann J, Wolf D, Pahl A, Brune K, Papadopoulos T, van Rooijen N, Tiegs G. Importance of Kupffer cells for T cell-dependent liver injury in mice. Am J Pathol 2000;157:1671-1683.
9. Gantner F, Leist M, Lohse AW, Germann P, Tiegs G. Concanavalin A-induced T cell-mediated hepatic injury in mice: the role of tumor necrosis factor. HEPATOLOGY 1995;21:190-198.
10. Küsters S, Gantner F, Künstle G, Tiegs G. Interferon-γ plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996;111:462-471.
11. Nicoletti F, Di Marco R, Zaccone P, Salvaggio A, Magro G, Bendtzen K, et al. Murine concanavalin A-induced hepatitis is prevented by interleukin 12 (IL-12) antibody and exacerbated by exogenous IL-12 through an interferon-γ-dependent mechanism. HEPATOLOGY 2000;32:728-733.
12. Faggioni R, Jones-Carson J, Reed DA, Dinarello CA, Feingold KR, Grunfeld C, et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A 2000;97:2367-2372.
13. Louis H, Le Moine O, Peny MO, Quertinmont E, Fokan D, Goldman M, et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. HEPATOLOGY 1997;25:1382-1389.
14. Di Marco R, Xiang M, Zaccone P, Leonardi C, Franco S, Meroni P, et al. Concanavalin A-induced hepatitis in mice is prevented by interleukin (IL)-10 and exacerbated by endogenous IL-10 deficiency. Autoimmunity 1999;31:75-83.
15. Mizuhara H, Kuno M, Seki N, Yu WG, Yamaoka M, Yamashita M, et al. Strain difference in the induction of T-cell activation-associated, interferon gamma-dependent hepatic injury in mice. HEPATOLOGY 1998;27:513-519.
16. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
17. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562.
18. + regulatory T cells mediate acquired transplant tolerance. Transpl Immunol 2003;11:287-293.
19. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
20. + regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol 2005;16:1360-1370.
21. Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: Back to the future. Semin Cancer Biol 2006;16:137-149.
22. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. HEPATOLOGY 2005;41:771-778.
23. + regulatory T cells. Nat Immunol 2003;4:330-336.
24. + regulatory T cells through glucocorticoid- induced TNF-receptor - related protein breaks immunological self-tolerance. Nat Immunol 2002;3:135-142.
25. + T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 2000;164:240-247.
26. + regulatory T cells. J Exp Med 2004;199:303-313.
27. + immunregulatory T cells suppress polyclonal T-cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-296.
28. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-310.
29. + regulatory T-cell activity in both humans and mice. J Immunol 2004;172:834-842.
30. Harber M, Sundstedt A, Wraith D. The role of cytokines in immunological tolerance: potential for therapy. Exp Rev Mol Med 2000;2000:1-20.
31. + T helper cells. J Exp Med 2002;196:255-260.
32. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004;114:1379-1388.
33. Van Kaer L. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol 2004;82:315-322.
34. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 1998;391:177-181.
35. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001;7:1052-1056.
36. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 2001;7:1057-1062.
37. Van Kaer L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstracles. Nat Rev Immunol 2005;5:31-42.
38. Kuhn R, Lohler J, Rennick D, Rajewsky K, Müller W. Interleukin-10-deficient mice develop chronic enterocholitis. Cell 1993;75:263-274.
39. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992;6:869-877.
40. Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L, et al. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 1997;6:469-477.
41. Biburger M, Tiegs G. α-Galactosylceramide-induced liver injury in mice is mediated by TNF-α but independent of Kupffer cells. J Immunol 2005;175:1540-1550.
42. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004;15:61-76.
43. + T lymphocytes. Proc Natl Acad Sci U S A 2005;102:11817-11822.
44. + T cells. Immunology 2005;115:305-314.
45. + regulatory, contact-dependent T cells induce Interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med 2002;19:247-253.
46. Cao Q, Batey R, Pang G, Russell A, Clancy R. IL-6, IFN-gamma and TNF-alpha production by liver-associated T cells and acute liver injury in rats administered concanavalin A. Immunol Cell Biol 1998;76:542-549.
47. Knolle PA, Löser E, Protzer U, Duchmann R, Schmitt E, zum Büschenfelde KHM, et al. Regulation of endotoxin-induced IL-6 production in liver entothelial cells and Kupffer cells by IL-10. Clin Exp Immunol 1997;107:555-561
48. Veldman C, Nagel A, Hertl M. Type I regulatory T cells in autoimmunity and inflammatory diseases. Int Arch Allergy Immunol 2006;140:174-183.
49. Grundstrom S, Cederbom L, Sundstedt A, Scheipers P, Ivars F. Superantigen-induced regulatory T cells display different suppressive functions in the presence or absence of natural CD4+CD25+ regulatory T cells in vivo. J Immunol 2003;170:5008-5017.
50. Louis H, Le Moine A, Quertinmont E, Peny MO, Geerts A, Goldman M, et al. Repeated concanavalin A challenge in mice induces an interleukin 10-producing phenotype and liver fibrosis. HEPATOLOGY 2000;31:381-390.